0.2806

4.55% -0.0172

IGC Pharma Inc (IGC)

Overview News Price History Option Chain Discussions Forecast Stock Split

IGC Pharma Inc stock is traded at $0.2806, with a volume of 865.81K. It is down -4.55% in the last 24 hours and up +9.33% over the past month. India Globalization Capital, Inc. engages in the development and commercialization of cannabis-based therapies to treat Alzheimer's, pain, nausea, eating disorders, several end points of Parkinson's, and epilepsy in humans, dogs, and cats. The company operates through two segments, Legacy Infrastructure and Medical Cannabis Based Alternative Therapies. The Legacy Infrastructure segment trades in infrastructure commodities, such as steel and iron ore; and rents heavy equipment. The Medical Cannabis Based Alternative Therapies segment offers IGC-501 for indications of neuropathic pain; Serosapse for indications of Parkinson's and other central nervous system disorders; Caesafin for seizures in cats and dogs; and Natrinol for indications of cancer and AIDS induced nausea and vomiting, as well as Hyalolex for Alzheimer's patients. The company was founded in 2005 and is based in Bethesda, Maryland.

Previous Close:

$0.2978

Open:

$0.2852

24h Volume:

865.81K

Relative Volume:

1.41

Market Cap:

$29.29M

Revenue:

$1.27M

Net Income/Loss:

$-7.12M

P/E Ratio:

-5.3755

EPS:

-0.0522

Net Cash Flow:

$-5.28M

1W Performance:

+6.26%

1M Performance:

+9.33%

6M Performance:

+11.04%

1Y Performance:

-23.15%

1-Day Range:

$0.2712

$0.2877

1-Week Range:

$0.27

$0.3031

52-Week Range:

$0.235

$0.4985

IGC Pharma Inc Stock (IGC) Company Profile

Name

IGC Pharma Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

301-983-0998

Address

4336 Montgomery Avenue, Bethesda, MD

Employee

Twitter

@IGCIR

Next Earnings Date

2026-08-13

Latest SEC Filings

IGC's Discussions on Twitter

Compare IGC vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IGC IGC Pharma Inc	0.2806	31.08M	1.27M	-7.12M	-5.28M	-0.0522
VRTX Vertex Pharmaceuticals Inc	515.44	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.90	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	992.82	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	215.68	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.27	39.31B	5.76B	514.49M	1.10B	4.4813

IGC Pharma Inc Stock (IGC) Latest News

02:20 AM

VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum - openPR.com

02:20 AM

10:59 AM

IGC Pharma Releases Q2 2026 Financial Results - AlphaStreet

10:59 AM

10:19 AM

IGC Pharma Q2 Results: Sales up 39% YoY, EPS loss widens to $(0.03) - scanx.trade

10:19 AM

10:07 AM

IGC Looks 24.1% Overvalued on GF Value™ - GuruFocus

10:07 AM

08:46 AM

IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure - Finviz

08:46 AM

08:32 AM

IGC Pharma Q2 Results: CALMA Nears Enrollment Closure - ACCESS Newswire

08:32 AM

Aug 14, 2026

IGC Pharma, Inc. 2026: Revenue $265K, EPS ($0.03) — 10-Q Summary - TradingView

Aug 14, 2026

IGC Pharma (NYSE: IGC) widens loss while Phase 2 Alzheimer’s trial hits key milestone - Stock Titan

Aug 14, 2026

IGC Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 14, 2026

Microcaps TOON, IGC, SURG, MDXH to Watch Now as Earnings, AI and Biotech Catalysts Build - openPR.com

Aug 14, 2026

Aug 13, 2026

IGC Pharma (NYSE American:IGC): What Does the Latest Update Mean for Clinical Development? - Kalkine Media

Aug 13, 2026

Aug 12, 2026

IGC Pharma (NYSE AMERICAN:IGC): What Could Today’s regulatory execution Update Reveal? - kalkinemedia.com

Aug 12, 2026

IGC Pharma (NYSE AMERICAN:IGC): What Could Today’s cannabinoid research progress Update Reveal? - Kalkine Media

Aug 12, 2026

Aug 11, 2026

Early Alert: PLAG, PRSO, UZX, IGC Lead Sub-$1 Stocks to WatchPlus More in Focus - openPR.com

Aug 11, 2026

Early Alert: PLAG, PRSO, UZX, IGC Lead Sub-$1 Stocks to Watch – Plus More in Focus - FinancialContent

Aug 11, 2026

IGC Looks 21.6% Overvalued on GF Value™ - GuruFocus

Aug 11, 2026

IGC Pharma Advances CALMA Toward Q4 Topline Readout - ACCESS Newswire

Aug 11, 2026

IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout - Corsicana Daily Sun

Aug 11, 2026

Aug 10, 2026

IGC Pharma Inc (IGS1.DU) balance sheet - Yahoo Finance UK

Aug 10, 2026